Clinical Insights & Updates
Immuron Limited is today pleased to announce the topline results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. The results show that oral IMM-124E shows improvement in liver injury with the potential for far-reaching opportunities beyond NASH.
Travelan was the focus of a comprehensive scientific study conducted by the Department of Enteric Disease. In our Scientific Review of Travelan, we unpack the research behind this US Army study where Travelan was tested against 180 different samples of bacteria collected from personnel with travellers’ diarrhoea. In addition we outline the clinical studies conducted on Travelan in Europe and the USA.
After further assessment, Red Chip analyst upgrades Immuron on C-Difficile Trial Result.
See Immuron CEO, Thomas Liquard's presentation for Red Chip Global Online CEO Conference